On March 29th, the NACI recommended provinces throughout Canada pause the use of the AstraZenaca-Oxford COVID-19 vaccine for those under the age of 55. This comes after reports out of Europe of very rare instances of blood clots in some immunized patients — notably among younger women. Vice chair of NACI, Dr. Shelley Deeks, spoke to reporters Monday, saying that with "substantial uncertainty around cases of vaccine-induced thrombocytopenia (VIPIT) in people with low platelets, the committee is recommending the suspension of shots in all people under 55 as a "precautionary measure."
In addition, it was reported by CBC that the “European Medicines Agency has said it could not definitively rule out a link between the vaccine and rare types of blood clots associated with thrombocytopenia.” And based on research thus far, VIPIT seems to be rare, occurring in anywhere from 1 in every 125,000 to 1 in 1 million people.
In the EMA’s press release, they “pointed to 18 cases of an extremely rare type of blood clot called cerebral venous sinus thrombosis (CVST), a condition that is much more common in women than men. Most of the cases occurred within 14 days of receivi...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).